¼¼°èÀÇ Æ¯¼ö Á¦³×¸¯ ½ÃÀå º¸°í¼­(2025³â)
Specialty Generics Global Market Report 2025
»óǰÄÚµå : 1656958
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,390,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,284,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ư¼ö Á¦³×¸¯ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ¿¬Æò±Õ 15.1%ÀÇ ¼ºÀå·ü(CAGR)·Î 2029³â±îÁö 1,897¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ È®´ë, º¹ÀâÇÑ Á¦³×¸¯ ÀǾàǰ °³¹ßÀÇ Á߿伺, Ư¼ö Á¦³×¸¯ ÁÖ»çÁ¦¿¡ ´ëÇÑ °ü½É Áõ°¡, Ư¼ö Á¦³×¸¯ Á¦Á¶¿¡ 3D ÇÁ¸°ÆÃ äÅÃ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ Æ¯¼ö Á¦³×¸¯ÀÇ ¼ºÀå¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¸ÂÃãÇü ¹× Ç¥ÀûÈ­µÈ Ư¼ö Á¦³×¸¯, Á¦³×¸¯ ÀǾàǰ °³¹ßÀÇ Àü·«Àû ÆÄÆ®³Ê½Ê ¹× Á¦ÈÞ, ¿À³²¿ë ¾ïÁ¦Á¦ °³¹ßÀÇ Á߿伺, Ư¼ö Á¦³×¸¯ÀÇ µðÁöÅÐ Çコ ±â¼ú ÅëÇÕ, º¹ÀâÇÑ Á¦³×¸¯ ÀǾàǰÀÇ ½ÂÀÎ °¡¼ÓÈ­¸¦ À§ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ³ë·Â µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ Áõ°¡´Â Ư¼ö Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÁúȯÀº °ü¸® ¹× ÅëÁ¦°¡ °¡´ÉÇÑ °æ¿ìµµ ÀÖÁö¸¸, ´ëºÎºÐ ºÒÄ¡º´ÀÌ µÉ ¼ö ÀÖ´Â Àå±âÀûÀÎ Áúº´ÀÔ´Ï´Ù. »ýȰ½À°üÀÇ º¯È­, ½Ä½À°ü Àå¾Ö, ºÎÀûÀýÇÑ Ã¼Áß °ü¸® µîÀÇ ¿äÀÎÀÌ ¸¸¼ºÁúȯÀÇ È®»ê¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ¸¸¼ºÁúȯÀÇ Àå±âÈ­·Î ÀÎÇØ ¾Ï ¹ß»ý À§ÇèÀÌ ³ô¾ÆÁö´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ ÀÌȯÀ²ÀÇ Áõ°¡´Â º¹ÀâÇÑ ¸¸¼ºÁúȯ Ä¡·á¿¡ ´ëÇÑ Æ¯¼ö Á¦³×¸¯ÀÇ Çʿ伺À» ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù ½ºÀ§½º¿¡ º»ºÎ¸¦ µÐ À¯¿£ Àü¹®±â±¸ÀÎ ¼¼°èº¸°Ç±â±¸(WHO)´Â ºñ°¨¿°¼º Áúȯ(NCDs) ¶Ç´Â ¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÚ°¡ Àü ¼¼°èÀûÀ¸·Î ¿¬°£ 4,100¸¸ ¸í¿¡ ´ÞÇϸç, ÀÌ´Â Àüü »ç¸ÁÀÚÀÇ 74%¸¦ Â÷ÁöÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. ±× Áß ½ÉÇ÷°üÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÌ 1,790¸¸ ¸í, ¾ÏÀ¸·Î ÀÎÇÑ »ç¸ÁÀÌ 930¸¸ ¸í, ¸¸¼º È£Èí±âÁúȯÀ¸·Î ÀÎÇÑ »ç¸ÁÀÌ 410¸¸ ¸í, ´ç´¢º´À¸·Î ÀÎÇÑ »ç¸ÁÀÌ 200¸¸ ¸íÀÔ´Ï´Ù. µû¶ó¼­ ¸¸¼ºÁúȯÀÇ ±ÞÁõÀº Ư¼ö Á¦³×¸¯ ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Àα¸ °í·ÉÈ­´Â ÇâÈÄ Æ¯¼ö Á¦³×¸¯ ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. '°í·ÉÈ­'´Â »çȸ ³» °í·ÉÀÚ ºñÀ²ÀÇ Áõ°¡¸¦ Ư¡À¸·Î ÇÏ´Â Àα¸Åë°èÇÐÀû º¯È­¸¦ ÀǹÌÇÕ´Ï´Ù. Ư¼ö Á¦³×¸¯Àº ¼ö¼ú ÈÄ ÅëÁõ, ±Þ¼º °¨¿°, ´Ü±â ÅëÁõ ¿ÏÈ­ µî ³ëÀο¡°Ô ¸¹ÀÌ ¹ß»ýÇÏ´Â ±Þ¼º Áõ»ó¿¡ ´ëóÇϱâ À§ÇØ Æ¯º°È÷ ó¹æµÇ´Â ÀǾàǰÀÔ´Ï´Ù. 2022³â 10¿ù ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ¿¹Ãø¿¡ µû¸£¸é, 2030³â¿¡´Â Àü ¼¼°è Àα¸ 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÇ °í·ÉÀÚ°¡ µÉ °ÍÀ̸ç, ±× ¼ö´Â 14¾ï ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°è 60¼¼ ÀÌ»ó Àα¸´Â µÎ ¹èÀÎ 21¾ï ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ °í·ÉÈ­´Â Ư¼ö Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Specialty generics refer to generic versions of drugs designed to replicate expensive, intricate, or high-touch generic medications. Managing specialty generics requires substantial service participation. This category encompasses biologics and biosimilars, each with distinct regulatory routes. Specialty medications, in general, are commonly used to treat various conditions such as malignancies, rheumatoid arthritis, and multiple sclerosis.

Specialty generics are administered through various routes, including injectables, oral, and others. The injectables route involves diverse methods of drug administration such as intravenous, subcutaneous, intradermal, intraperitoneal, intramuscular, and others. This is applicable in the treatment of medical conditions ranging from cancer to autoimmune disorders. Drug injection typically involves the use of a hollow hypodermic needle to introduce a substance into the bloodstream. Specialty generics find applications in indications like oncology, autoimmune diseases, infectious diseases, and others. These medications are distributed through multiple channels, including retail pharmacies, specialty pharmacies, and hospital pharmacies.

The specialty generics market research report is one of a series of new reports from The Business Research Company that provides specialty generics market statistics, including specialty generics industry global market size, regional shares, competitors with a specialty generics market share, detailed specialty generics market segments, market trends and opportunities, and any further data you may need to thrive in the specialty generics industry. This specialty generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The specialty generics market size has grown rapidly in recent years. It will grow from $95.87 billion in 2024 to $108.11 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to patent expirations of brand-name drugs, growing demand for cost-effective alternatives, regulatory support for generic drug approvals, increasing healthcare cost pressures, rise in chronic diseases and aging population.

The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $189.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to expansion of biosimilars market, emphasis on complex generic drug development, increasing focus on specialty generic injectables, adoption of 3d printing in specialty generic manufacturing, growth of specialty generics in emerging markets. Major trends in the forecast period include personalized and targeted specialty generics, strategic partnerships and collaborations in generic drug development, focus on developing abuse-deterrent formulations, integration of digital health technologies in specialty generics, regulatory initiatives for accelerated approval of complex generics.

The increase in chronic diseases is projected to boost the demand for the specialty generic market. Chronic diseases are long-term illnesses that are often incurable, although some can be managed or controlled. Factors such as changing lifestyles, poor eating habits, and inadequate weight management contribute to the prevalence of chronic conditions, with some extended chronic illnesses heightening the risk of cancer. The rising incidence of these diseases amplifies the need for specialty generics to treat complex chronic conditions. For example, in September 2022, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths annually-accounting for 74% of deaths from non-communicable diseases (NCDs) or chronic diseases-occur globally. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the surge in chronic diseases is fueling the growth of the specialty generic market.

The aging population is expected to propel the specialty generic market in the future. The term 'aging population' denotes the demographic shift characterized by a rising proportion of elderly individuals in a society. Specialty generics are specifically formulated pharmaceuticals designed to address acute conditions prevalent in the elderly, such as postoperative pain, acute infections, or short-term pain relief. This ensures effective treatment options for the aging population while managing healthcare costs. According to the World Health Organization's projections in October 2022, by 2030, one out of every six individuals globally will be 60 years or older, reaching 1.4 billion. By 2050, the global population of individuals aged 60 and older is expected to double to 2.1 billion. Therefore, the aging population is a significant driver for the specialty generic market.

Major companies in the specialty generic market are obtaining approvals for medications like Lisdexamfetamine Dimesylate to address critical medical needs. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that are bioequivalent and therapeutically equivalent to brand-name specialty drugs. In August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for Lisdexamfetamine Dimesylate Capsules in SpecGx LLC Specialty Generics segment to treat Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine Dimesylate, a federally controlled substance (CII), is used for ADHD and other indications.

Major companies in the specialty generic market are introducing new products to offer more affordable alternatives. In March 2022, Teva Pharmaceutical Industries Ltd, an Israel-based pharmaceutical company, launched the first generic version of REVLIMID (lenalidomide) in the US, available in 5mg, 10mg, 15mg, and 25mg capsules. REVLIMID is prescribed for adults with multiple myeloma (MM) and is used either in combination with dexamethasone or as a maintenance treatment post-autologous hematopoietic stem cell transplantation.

In October 2022, Aspire Pharma, a UK-based pharmaceutical company, acquired Morningside Pharmaceuticals and Morningside Healthcare, including its subsidiaries like Morningside Healthcare (India), for an undisclosed amount. This strategic acquisition aims to expand Aspire Pharma's market position by combining complementary product portfolios, providing added talent, an increased in-market range, and an industry-leading pipeline, positioning the company as a premier specialty generic pharmaceutical organization.

Major companies operating in the specialty generics market include Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

North America was the largest region in the specialty generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the specialty generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The specialty generics market consists of sales of biologics and biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specialty Generics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on specialty generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for specialty generics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specialty generics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Specialty Generics Market Characteristics

3. Specialty Generics Market Trends And Strategies

4. Specialty Generics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Specialty Generics Growth Analysis And Strategic Analysis Framework

6. Specialty Generics Market Segmentation

7. Specialty Generics Market Regional And Country Analysis

8. Asia-Pacific Specialty Generics Market

9. China Specialty Generics Market

10. India Specialty Generics Market

11. Japan Specialty Generics Market

12. Australia Specialty Generics Market

13. Indonesia Specialty Generics Market

14. South Korea Specialty Generics Market

15. Western Europe Specialty Generics Market

16. UK Specialty Generics Market

17. Germany Specialty Generics Market

18. France Specialty Generics Market

19. Italy Specialty Generics Market

20. Spain Specialty Generics Market

21. Eastern Europe Specialty Generics Market

22. Russia Specialty Generics Market

23. North America Specialty Generics Market

24. USA Specialty Generics Market

25. Canada Specialty Generics Market

26. South America Specialty Generics Market

27. Brazil Specialty Generics Market

28. Middle East Specialty Generics Market

29. Africa Specialty Generics Market

30. Specialty Generics Market Competitive Landscape And Company Profiles

31. Specialty Generics Market Other Major And Innovative Companies

32. Global Specialty Generics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Specialty Generics Market

34. Recent Developments In The Specialty Generics Market

35. Specialty Generics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â